SARS-CoV-2 Infection in Patients with a History of VITT

The study investigates SARS-CoV-2 infection in patients with a history of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), a rare adverse effect of adenovirus vector-based COVID-19 vaccines. The research evaluated 69 patients with VITT, 11 of whom contracted COVID-19. Findings indicate that COVID-19 did not trigger an increase in anti-PF4 antibodies or recurrent thrombotic events in these patients, supporting the independence of immune responses against SARS-CoV-2 spike protein and PF4. The study also suggests that mRNA vaccines are a safer option for subsequent vaccination in VITT survivors.

The study investigates SARS-CoV-2 infection in patients with a history of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), a rare adverse effect of adenovirus vector-based COVID-19 vaccines. The research evaluated 69 patients with VITT, 11 of whom contracted COVID-19. Findings indicate that COVID-19 did not trigger an increase in anti-PF4 antibodies or recurrent thrombotic events in these patients, supporting the independence of immune responses against SARS-CoV-2 spike protein and PF4. The study also suggests that mRNA vaccines are a safer option for subsequent vaccination in VITT survivors.